



2020 North America Conference on Lung Cancer

OCTOBER 16-17, 2020 | WORLDWIDE VIRTUAL EVENT

#NACLC20

VIRTUAL CONFERENCE

Preliminary Program

All times CDT

Friday, October 16, 2020

13:00 – 14:00 **Welcome and Opening Address**

Chairs: Heather Wakelee, USA & Ken Rosenzweig, USA

- Chair's Welcome
- Lung Ambition Alliance Update – Chandra Belani, USA
- Patient Perspective: COVID Survivor – Bob Steele, USA
- Opening Address - Real World Practical Application (Effects of COVID-19 on Lung Cancer Care and Implications) – Marina Garassino, Italy

14:00 – 15:05 **Immunotherapy**

Chair: Ticiana Leal, USA

- Patient Perspective: Immunotherapy – John Ryan, USA
- IO Therapy for Stage IV Therapies – Nasser Hanna, USA
- PACIFIC Nuances and What's Next? – Jhanelle Gray, USA
- Combining IO with Radiation Therapy – Steve Chmura, USA
- Moving IO Into Early Stage Disease – Linda Martin, USA
- In Search of the Perfect Biomarker for IO – Lynette Sholl, USA

15:05 – 15:20 **Break**

15:20 – 17:00 **Oral Abstract Session 1**

Chair: Everett Vokes

- Patient Perspective – John, Doll, USA
- Nivolumab (NIVO) + Ipilimumab (IPI) + 2 Cycles of Platinum-doublet Chemotherapy (Chemo) vs 4 Cycles Chemo as First-line (1L) Treatment) for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC): CheckMate 9LA – David Carbone, USA
- Nivolumab (NIVO) + Ipilimumab (IPI) Versus Platinum-doublet Chemotherapy (Chemo) as First-line (1L) Treatment for Advanced Non-small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1 – Julie Brahmer, USA
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer – Jie Wang, China
- Discussant: Deborah Doroshow, USA
- Live Q&A Moderated by Everett Vokes, USA
- Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study – Timothy Yap, USA
- Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-induced Myelosuppression – Renata Ferrarotto, USA
- Discussant: Melina Marmarelis, USA
- Live Q&A Moderated by Everett Vokes, USA
- Tobacco Moment: Lung Cancer Screening and Smoking Cessation Clinical Trials (SCALE) Collaboration (NIH Study) – Stephanie Land, USA



2020 North America Conference on Lung Cancer

OCTOBER 16-17, 2020 | WORLDWIDE VIRTUAL EVENT

#NACLC20

VIRTUAL CONFERENCE

Preliminary Program

All times CDT

17:00 – 18:00 Virtual Posters and Virtual Exhibit Hall

18:00 – 18:20 Press Conference

Saturday, October 17, 2020

07:00 – 07:50 **Oligometastatic Lung Cancer**

Chair: Jyoti Patel, USA & Daniel Gomez, USA

- Chair's Welcome
- Patient Perspective: Oligometastatic Lung Cancer – Frank Sieawski, USA
- Rationale for Aggressive Local Therapy in Metastatic Disease - Who to Refer and When? – Sawsan Rashdan, USA
- Surgery for Local Consolidated Therapy for Patients with Oligometastatic Disease – Erin Gillaspie, USA
- Radiation for Local Consolidation Therapy – Tim Kruser, USA

07:50 – 09:35 **Oral Abstract Session 2**

Chair: Phil Bonomi, USA

- Patient Perspective – Melissa Crouse, USA
- Analysis of Resistance Mechanisms to Pralsetinib in Patients with RET Fusion-positive Non-small Cell Lung Cancer (NSCLC) from the ARROW Study – Justin Gainor, USA
- Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A – Julien Mazieres, France
- Real-World Progression-Free Survival in Oncogenic Driver-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Single-Agent Immunotherapy – Joseph Bodor, USA
- Discussant: Joel Neal, USA
- Live Q&A Moderated by Phil Bonomi, USA
- Lung Cancer Screening Modifies Smoking Behavior – Monica Reyes, USA
- Trends of Incidence and Burden of Metastatic Disease at Diagnosis of Lung Cancer after Implementation of Low Dose CT Screening in the United States – Manoj Rai, USA
- Volume Doubling Time and Radiomic Features Predict Tumor Behavior of Screen-detected Lung Cancers in the National Lung Screening Trial (NLST)- Jaileene Perez-Morales, USA
- Discussant: Betty Tong, USA
- Live Q&A Moderated by Phil Bonomi, USA
- Tobacco Moment: Practicalities of Delivering Smoking Cessation Services in the Era of Telehealth – Bill Evans, USA

09:35 – 09:50 **Break**



Preliminary Program

All times CDT

09:50 – 10:45

Targeted Therapy

Chair: Taofeek Owonikoko, USA

- Patient Perspective: Targeted Therapies – Frances Beard, USA
- Tobacco Product Update and Myth Busters – Mike Cummings, USA
- The Newest FDA Approvals for Targeted Therapies – Charu Aggarwal, USA
- Panel Discussion: What Research Patients Have Contributed – Ivy Elkins, USA & Janet Freeman-Daily, USA
- Should Targeted Therapy Be 1st Line (Over Chemo, IO, or Chemo Plus IO) in All Patients, Regardless of the Targetable Mutations (e.g. ROS-1, RET, MET)? – Zofia Piotrowska, USA
- Beyond Tissue – Lynette Sholl, USA

10:45 – 11:50

Tumor Board – Stage III Case

- Patient Perspective – AJ Patel, USA
- Case Presentation – Christine Bestvina, USA
- Panel:
 - Ken Rosenzweig, USA
 - Rafael Santana-Davila, USA
 - Greg Durm, USA
 - Jessica Donington, USA

10:45 – 11:50

Tumor Board – SCLC with Pathology Case

- Patient Perspective – AJ Patel, USA
- Case Presentation – Neal McCall, USA
- Panel:
 - Kristin Higgins, USA
 - Christine Hann, USA
 - Taofeek Owonikoko, USA
 - Brian Kavanaugh, USA

11:50 – 12:40

Keynote Address

Chair: Everett Vokes, USA

- Paradigm Shift in Early Stage Disease – Mary Jo Fidler, USA
- What Does It Mean for Patients? – Jill Feldman, USA
- What Does It Mean For Surgeons? – Matthew Steliga, USA
- Tobacco Control Moments: Effective Integration of Smoking Cessation Services Across the Lung Cancer Continuum – Joelle Fathi, USA
- Closing Remarks – Julie Brahmer, USA & Jessica Donington, USA



Preliminary Program

All times CDT

On Demand Content

SCLC

- Strategies for Adding Immunotherapy in First Line SCLC – Shadia Jalal, USA
- What Is the Preferred 2nd Line Treatment of Small Cell Lung Cancer: Immunotherapy, Topotecan, or Lurbinectedin? – Karen Kelly, USA
- Advances in Radiation for SCLC – Alexander Louie, Canada

Mesothelioma

- Immune-checkpoint Inhibitors for Malignant Mesothelioma – Patrick Forde, USA
- Induction Strategies for Malignant Mesothelioma – Bryan Burt, USA
- IMRT Following ext P/D for Mesothelioma – Andreas Rimner, USA

Lung Cancer Screening

- Lung Cancer Experience in the VA System; Lessons Learned – Anne Melzer, USA
- How to Overcome the Negative Impact of COVID-19 on Deferred Lung Cancer Screening – Nichole Tanner, USA
- Updated Guidelines for Lung Cancer Screening: The Impact of Screening in Minorities – Summer Han, USA

Risk Reduction and Tobacco Control

- Criticality of Tobacco Use Assessment in Clinical Trials – Matt Steliga, USA
- Recent FDA Marketing Decision on Heated Tobacco – Maciej Goniewicz, USA

SBRT for Lung Cancer

- Radiomics for Lung SBRT Dose Selection – Mohamed Abazeed, USA
- SBRT vs Lobectomy; The Ongoing VA Randomized Study (VALOR) – David Harpole, USA

2nd Line Therapy

- Should You Continue PD-1/PD-L1 Blockade at the Time of Disease Progression in a Patient That Has Previously Benefited from IO Therapy? – Ticiana Leal, USA
- How Common is Small Cell Transformation in Oncogene-driven Lung Cancer Such as EGFR and ALK? How Can It Be Treated? – Ryan Gentzler, USA
- 2nd Line Therapy Potpourri – Taofeek Owonikoko, USA

Surgery for Early Stage

- Decreasing Opioid Use for Thoracic Surgery – Brendon Stiles, USA
- The Role of Salvage Surgery After SBRT or After Pacific Regimes – Mara Antonoff, USA
- Understanding Commission on Cancer Rules – Daniel Boffa, USA

Patient Survivorship

- Conversations on the Topics of Survivorship and Quality of Life – Laura Petrillo, USA & Sarah Knox, USA



Preliminary Program

All times CDT

Featured Posters

- Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study - Xiuning Le, USA
- KEYNOTE-021 Cohort G Long-term Follow-up: First-line (1L) Pemetrexed and Carboplatin (PC) With or Without Pembrolizumab for Advanced Nonsquamous NSCLC - Mark M. Awad, USA
- Systemic and Intracranial Efficacy of Brigatinib vs Crizotinib: Updated Results from the ALTA-1L Trial - Sanjay Popat, UK
- Improving Quality of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in the Mid-south US - Matthew Smeltzer, USA
- Circulating Ensembles of Tumor Associated Cells Facilitate Efficient Triaging of Asymptomatic Individuals for Low Dose Computed Tomography - Dadasaheb Akolkar, USA
- Improving Rural Disparity in Lung Cancer Outcomes Starting With An Academic-Community Network Model of LDCT Screening - Charles Shelton, USA
- Delayed ALK Testing Results in the US - Analysis With a Large Real World Oncology Database - Eric Bernicker, USA
- Tolerability, Low-Fat Meal Effect, and Relative Bioavailability (BA) of Oral EGFR Inhibitor TAK-788 in Healthy Volunteers - Steven Zhang, USA
- Economic Burden of Metastatic Non-Small Cell Lung Cancer (mNSCLC) in a Large United States (US) Claims Database - Brian Seal, USA

Posters

Community Practice

- Utilization of Cancer Immunotherapy Prior to Biomarker Test Results Among Patients With Advanced Non-small Cell Lung Cancer in US Community Settings - Aaron Mansfield, USA
- Improving Care for Patients With Stage III/IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey - Leigh Boehmer, USA
- COVID 19's Pandemic 's Effect on a Community Lung Cancer Screening Program - Goetz Kloecker, USA
- Biomarker Testing Among Users of Online Lung Cancer Resources - Can Online Communities Make a Clinical Impact? - Margot Tishberg, USA
- Relapse Rate and Associated Healthcare Resource Utilization in Stage IIA-IIIB Adjuvant NSCLC Patients Treated in a US Oncology Community Network - Beilei Cai, USA
- Veterans Affairs Insurance Disparities for Metastatic Lung Cancer in the Hawaiian Islands - Stephen Chun, USA

Immunotherapy

- 4-year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs Docetaxel in 2L+ NSCLC - Julien Mazieres, France



Preliminary Program

All times CDT

Medical Oncology

- Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy - Jacqueline V. Aredo, USA
- Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-line Treatment of Metastatic Non-small Cell Lung Cancer in the United States - Malin Berling, USA
- Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations - Beilei Cai, USA
- Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial - Kelly Goodwon, USA
- Treatment Patterns in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in the Era of Immunotherapy (IO) - David Stenehjem, USA
- Real-World Outcomes of Immunotherapy-based Regimens in First-line Advanced Non-small Cell Lung Cancer - David Waterhouse, USA
- Incidence of Aggressive End of Life Measures in a Retrospective Cohort of High-Risk Patients with Advanced Lung Cancer Receiving Immunotherapy - Ankur Singh, USA
- Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders - Vivek Subbiah, USA
- Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics - Jacob Sands, USA
- Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge - Vivek Subbiah, USA
- The Relative Survival Impact of Thorough Staging and Appropriate Treatment in Non-Small-Cell Lung Cancer (NSCLC). - Meghan Taylor, USA
- Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy - Joseph Mock, USA
- Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-squamous Non-small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy - Gavitt Woodard, USA
- Real-world Effectiveness and Safety of Afatinib Following Immunotherapy (IO) in the Treatment of Metastatic, Squamous Cell/Mixed Histology Carcinoma of the Lung: A Multi-site Retrospective Chart Review Trial in the US - Edward Kim, USA
- Nitric Oxide Lung Cancer Active Vaccination - Hila Confino, USA
- Sociodemographic and Contextual Factors Associated with Biomarker Testing for Patients with Non-Small Cell Lung Cancer in Community Practice - Louise Henderson, USA
- Real-world Characteristics and Outcomes of Advanced NSCLC Patients with Exon 19 or 21 EGFR Mutations - Katherine Winfree, USA
- An Indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-line Therapies in Patients with PD-L1 TPS \geq 1% Metastatic NSCLC - Balazs Halmos, USA
- An Indirect Comparison of Pembrolizumab Monotherapy versus Ipilimumab+Nivolumab for first-line Metastatic NSCLC with PD-L1 TPS \geq 1% - Balazs Halmos, USA



Preliminary Program

All times CDT

- Pembrolizumab+Chemo versus Atezolizumab+Chemo+/-Bevacizumab for First-line Nonsquamous NSCLC: A Matching-adjusted Indirect Comparison - Balazs Halmos, USA
- Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-small Cell Lung Cancer Who Received Prior Immunotherapy - Rebecca S. Heist, USA
- Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial - Alexander I. Spira, USA
- Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-N Trial - Jay Lee, USA
- Presentation and Radiographic Characteristics of Leptomeningeal Disease (LMD) in Non-small Cell Lung Cancer (NSCLC) - Cristina Merkhofer, USA
- Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma - Jacqueline V. Aredo, USA
- Second Primary Lung Cancer with NTRK1 Mutation after Initial Primary mEGFR Lung Cancer - Goetz Kloecker, USA
- Three-year follow-up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, as Second-line (2L) Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) - Luis Paz-Ares, Spain
- A Phase 1b/2, Open-label Study of Bintrafusp Alfa with Chemotherapy in Patients with Stage IV Non-small Cell Lung Cancer - Italia Grenga, USA
- Randomized, Open-label Study of Bintrafusp Alfa vs Pembrolizumab as First-line (1L) Treatment in Patients with PD-L1-expressing Advanced Non-small Cell Lung Cancer (NSCLC) - Everett Vokes, USA
- Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with Other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreak101) - Marwan Fakih, USA
- Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor - D Hong, USA
- CodeBreak 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation - Martin Reck, USA
- CRESTONE – Clinical Study of Response to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) - David Spigel, USA
- Patients with Solid Tumors Harboring NRG1 Gene Fusions: A Real-world Feasibility Study - Sushma Jonna, USA
- Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer - Alexander Drilon, USA
- Afatinib in Asian and Non-Asian patients (pts) with EGFR Mutation-positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations - James Chih-Hsin Yang, Taiwan
- Sequential Afatinib and Osimertinib in Real-world EGFR Mutation-positive (EGFRm+) NSCLC Patients: Final Analysis of the GioTag Study - Maximilian Hochmair, Germany
- Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-small-cell Lung Cancer (NSCLC) - Justin Gainor, USA
- Liposomal Irinotecan in Adults with Small Cell Lung Cancer Who Progressed on Platinum-based Therapy: Subgroup Analyses by Platinum Sensitivity - David R. Spigel, USA
- Trilaciclib Has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age - Thaddeus Beck, USA



Preliminary Program

All times CDT

- Using an Exploratory Composite Endpoint to Evaluate the Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer - Janakiraman Subramanian, USA
- Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions - Maen Hussein, USA
- Examining the Impact of Tislelizumab Added to Platinum Doublet Chemotherapy on Health-Related Quality of Life in Patients with Non-Squamous NSCLC - Shun Lu, China
- Prognostic Factors in Extensive-Stage Small Cell Lung Cancer (SCLC) - Susana Baptista De Almeida, Portugal
- Health-related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib - Marina Garassino, Italy
- Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC - Santiago Viteri, Spain
- Tepotinib Exposure-response Analyses of Safety and Efficacy in Patients with Solid Tumors - Wenyuan Xiong, USA
- INSIGHT 2: Tepotinib + Osimertinib in EGFR-mutant NSCLC with Resistance to 1st-line Osimertinib Due to MET Amplification - Egbert Smit, Netherlands
- Low Prognostic Nutrition Index Predicts Poorer Quality of Life in Late Stage Lung Cancer - Li Gengpeng, China
- Tislelizumab Plus Standard Chemotherapy for Treatment of Advanced Squamous Non-Small Cell Lung Cancer: Patients' Health Related Quality of Life - Wang, Jie, China

Nursing & Allied Health

- Real World Data on Maintenance Therapy Utilization and Overall Survival Among Advanced Non-Small Cell Lung Cancer Patients Treated with Pemetrexed in Combination with Pembrolizumab and Platinum Chemotherapy in the US - Kayonda Bayo, USA

Oligometastatic

- Real-world Clinical Outcomes in Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) in the US - E Nadler, USA

Pathology

- Diagnostic and Economic Value of Next-generation Sequencing (NGS) in Genotyping Non-small Cell Lung Cancer Tumors (NSCLC): A Literature Review - Ying Zheng, USA
- Diagnostic and Economic Value of Liquid vs. Solid Tissue Biopsy Procedures for the Detection of Targetable Mutations in Non-small Cell Lung Cancer (NSCLC) Tumors: A Literature Review - Ying Zheng, USA
- Mutational Landscape and Prognosis Prediction for Immune Checkpoint Blockades of DNA Damage Response Pathways in Non-Small Cell Lung Cancer - Jing Zhao, USA



Preliminary Program

All times CDT

Prevention, Smoking Cessation, Screening and Early Detection

- Evaluation of Circulating Tumor Cells for Non-Invasively Discerning Lung Primary from Metastasis - Darshana Patil, India
- Smoking Cessation after Lung Cancer Diagnosis and Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study - Eunji Choi, USA
- A Novel 27-gene Signature Associated with Better Outcomes for NSCLC Patients Treated with IO Therapies with PD-L1 Expression >50%. - David Hout, USA
- A Novel Immunomodulatory Signature Improves Prediction of Response to Immunotherapy Compared to PD-L1 IHC in NSCLC Patients. - David Hout, USA
- Racial Differences in Eligibility for Low Dose CT Screening and Burden of Metastatic Disease at Diagnosis of Lung Cancer in the United States - Manoj P Rai, USA
- Integrating Circulating Genetically Abnormal Cells to Early Lung Cancer Screening in Chinese Bus Drivers - Xiaozheng Yang, China
- Predicting Changes in Lung Cancer Risk in the At-Risk Screen Ineligible Population - Andrew CL Lam, Canada
- Simultaneous Multi-Cancer Detection and Tissue of Origin Prediction Via Targeted Bisulfite Sequencing of Plasma Cell-Free DNA - Kathryn Kurtzman, USA

Pulmonary

- Ground Glass Opacity: What's in a Name? - Eric L. Flenaugh, USA
- AcceleRET Lung: A Phase 3 Study of First-line Pralsetinib in Patients with RET-fusion+ Advanced/Metastatic NSCLC - Benjamin Besse, France
- Effect of Tumor Size Change and Duration of Response on OS With First-Line Pembrolizumab Plus Pemetrexed-platinum For Metastatic Nonsquamous Non-Small-Cell Lung Cancer - Steven F. Powell, USA

Radiation Oncology

- Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis - Aditya Juloori, USA

Targeted Therapy

- Real-world Outcomes in Patients with EGFR/ALK-positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy - P Cheema, Canada
- Emergence of NOTCH2-NTRK1 after Osimertinib in a Patient with Lung Adenocarcinoma with Neuroendocrine Differentiation - Li Gengpeng, China



2020 North America Conference on Lung Cancer

OCTOBER 16-17, 2020 | WORLDWIDE VIRTUAL EVENT

#NACLC20

VIRTUAL CONFERENCE

Preliminary Program

All times CDT

- Drug-Drug Interaction of Oral EGFR Inhibitor TAK-788 With Itraconazole and Rifampin in Healthy Volunteers - Steven Zhang, USA

Translational Science

- HIF-1a Upregulates Muscarinic Receptor 3 and Promotes Invasion and Metastasis in NSCLC - Li Gengpeng, China
- Novel Anti-CTLA-4 Antibody Quavonlimab Plus Pembrolizumab as First-line Therapy for NSCLC: Extended Follow-up from a Phase 1 Study - Byoung Chul Cho, China
- Efficacy and Safety Data From a Phase 1/2 Trial of Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) - Qing Zhou, China
- Racial Disparity in the Timely Treatment of Non-small Cell Lung Cancer - Paige Neroda, USA
- Timely Treatment and Survival for Localized Lung Cancer - Lu Zhang, USA
- High-Plex Digital Spatial Profiling of Non-small-cell Lung Cancer (NSCLC) - Arutha Kulasinghe, Australia
- Genomic HLA as a Predictive Biomarker for Survival Among Non- small Cell Lung Cancer Patient Treated with Single Agent Immunotherapy. - Afaf Abed, Australia